SBDS Activators
The chemical class termed SBDS Activators encompasses a group of compounds capable of modulating the activity of the Shwachman-Bodian-Diamond Syndrome protein (SBDS), which is encoded by the SBDS gene. While explicit direct activators for SBDS may not be identified, these compounds exert their effects through various mechanisms, influencing pathways associated with inflammation, histone modifications, and cellular processes influenced by SBDS. Activators of this class operate by modulating the Wnt/β-catenin signaling pathway. This suggests a potential indirect avenue for influencing SBDS activity through the intricate dynamics of Wnt signaling. Similarly, iactivators. are implicated in affecting SBDS by influencing the cyclooxygenase pathway, indicating a potential connection between inflammation processes and the modulation of SBDS function.
Furthermore, activators of this class may activate SBDS through its influence on histone deacetylase, suggesting a role in epigenetic regulation and offering insights into how SBDS activity may be modulated through changes in chromatin structure. Activators may initate SBDS through interactions with peroxisome proliferator-activated receptor gamma (PPAR-γ), establishing a link between SBDS and cellular processes related to metabolism and inflammation. Collectively, these compounds showcase the diverse mechanisms through which SBDS Activators may impact SBDS activity. This chemical class provides a spectrum of potential avenues for influencing the cellular functions relevant to Shwachman-Bodian-Diamond Syndrome, opening new avenues for understanding and potentially manipulating SBDS activity in various contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride may potentially activate SBDS by modulating cellular processes associated with the Wnt/β-catenin signaling pathway. Activation of this pathway can influence SBDS activity, although the exact mechanism remains unclear. Lithium chloride has been implicated in Wnt pathway regulation, suggesting a potential indirect activation of SBDS through its impact on Wnt/β-catenin signaling. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), may activate SBDS by affecting the cyclooxygenase (COX) pathway. Its anti-inflammatory properties involve inhibiting COX, influencing cellular processes related to inflammation and potentially modulating SBDS activity. While the exact connection between COX inhibition and SBDS activation requires further investigation, indomethacin stands out as a compound with potential implications in this context. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, an anticonvulsant and mood-stabilizing drug, may activate SBDS by influencing histone deacetylase (HDAC) activity. Its role in histone acetylation dynamics suggests a potential impact on SBDS function. Valproic acid's ability to modulate HDACs can potentially affect cellular processes relevant to SBDS, highlighting its candidacy as a compound that may indirectly activate SBDS through epigenetic regulation. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate, a salt form of butyric acid, may activate SBDS similarly to butyrate. Its impact on histone deacetylation suggests a potential role in modulating SBDS activity through epigenetic regulation. Sodium butyrate's influence on cellular processes related to histone modifications and gene expression provides a rationale for considering it as a compound that can potentially activate SBDS in relevant cellular contexts. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a potent histone deacetylase inhibitor, may activate SBDS by affecting histone acetylation dynamics and chromatin remodeling. Its role in modulating gene expression suggests a potential impact on SBDS activity. Trichostatin A's ability to influence epigenetic regulation provides a basis for considering it as a compound that may indirectly activate SBDS through its effects on histone modifications. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid may activate SBDS through its involvement in cellular processes related to retinoid signaling. Its impact on gene expression and differentiation suggests a potential role in modulating SBDS activity. Retinoic acid's connection to cellular pathways relevant to SBDS provides a rationale for considering it as a compound that may indirectly activate SBDS in specific cellular contexts. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea may activate SBDS by influencing cellular processes associated with DNA synthesis and repair. Its impact on DNA damage response pathways suggests a potential role in modulating SBDS activity. Hydroxyurea's connection to DNA-related cellular functions provides a basis for considering it as a compound that may indirectly activate SBDS in contexts involving DNA damage and repair mechanisms. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone may activate SBDS by interacting with cellular pathways involved in immune response and inflammation. Its anti-inflammatory properties can potentially influence SBDS activity, although the precise mechanisms require further exploration. Dexamethasone's impact on cellular processes related to immune regulation and inflammation positions it as a candidate for indirect activation of SBDS. | ||||||